NCT07318337Completed
Effect of Drospirenone-Ethinyl Estradiol (20microgram vs 30 Microgram) on Free Androgen Index in PCOS
Effect of Drospirenone-Ethinyl Estradiol (20µg) in Comparison to Drospirenone-Ethinyl Estradiol (30µg) on Free Androgen Index in Polycystic Ovary Syndrome
Source: ClinicalTrials.gov · Last updated 9 Jan 2026
Brief summary (registry, in English)
Combined hormonal contraceptive (CHC) improves androgen parameter in women with PCOS. High-dose CHC increases insulin resistance, whereas low dose CHC has minimal effects on carbohydrate metabolism. This quasi experimental study was conducted to compare the effects of Drospirenone-Ethinyl Estradiol (20µg) to that with Drospirenone-Ethinyl Estradiol (30µg) on free androgen index (FAI) in polycystic ovary syndrome. Medication was given for 3 months. FAI, HOMA-IR was measured in baseline and after treatment and results were compared.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 60 (actual)
- First submitted
- 23 Dec 2025
- Start date
- Jul 2024
- Primary completion date
- Jun 2025
- Lead sponsor
- Mst.Sumyara Khatun
- NCT number
- NCT07318337
What you commit to
- Study type: Interventional
- Participants enrolled: 60
- From Jul 2024 to the primary completion date, Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Contraindication of OCP such as history of thromboembolic disorder, cerebrovascular disease, coronary artery disease, carcinoma of breast or other estrogen dependent neoplasm, undiagnosed abnormal genital bleeding, known or suspected pregnancy, benign or malignant liver neoplasm, cholestatic jaundice on previous pregnancy, abnormal liver and renal function, uncontrolled DM and HTN, dyslipidemia, history of migraine with focal aura
Other
- Recent use of androgen and antiandrogens within 3months
- BMI\>30kg/m2
- Cause of oligovulation other than PCOS
Who the study is looking for
- Diagnosed case of PCOS patients according to Rotterdam criteria
- women with PCOS
Age in the registry: 18 years to 35 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Bangladesh Medical University Coordinator of this site? Confirm its status | Dhaka | Bangladesh | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.